Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) | PAR 25 210

FAQs: Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) (PAR-25-210)

What is the goal of this NIH funding opportunity?

The goal is to fund mechanistic research that explains why probiotics benefit some people but not others, and to use that mechanistic insight to improve the reliability of probiotic interventions. The focus is on "precision probiotic therapy," meaning projects should connect person-specific host characteristics to differences in probiotic response and outcomes.

What does "precision probiotic therapy" mean in this program?

In this program, precision probiotic therapy refers to identifying which host-specific characteristics shape probiotic response, defining distinct responder subgroups based on those characteristics, and using mechanistic understanding to improve clinical outcomes or intervention performance. The emphasis is on moving past one-size-fits-all probiotic approaches.

What kind of research does NIH want to fund here: efficacy testing or mechanism?

This opportunity is aimed at mechanism. Rather than only testing whether a probiotic works on average, projects are expected to uncover biological reasons behind variable or inconsistent results in human studies and translate those findings into strategies that make responses more consistent and predictable.

What does "mechanistic research" mean in the context of this NOFO?

"Mechanistic" means going beyond descriptive associations and testing how and why a host factor changes probiotic function or host response. The NOFO emphasizes approaches that can distinguish correlation from causality and explain pathways such as colonization, persistence, metabolic activity, immune modulation, or other biological processes that drive differential responses.

What is the central scientific issue this program is trying to address?

A central issue is heterogeneity in human hosts and how that heterogeneity leads to variable probiotic effects. The program is designed to explain why the same probiotic strain or intervention can perform differently across individuals.

What are examples of "host biological patterns" that applicants are expected to study?

The NOFO provides examples such as native microbiome composition and function, immune status, sex- or gender-related biology, diet, age, genetic background, lifestyle factors, and relevant health history. Projects should evaluate whether such patterns can detect, predict, or explain improved probiotic responsiveness.

How should applicants connect host patterns to probiotic outcomes?

Projects should aim to link measurable host features to differences in mechanistic pathways, including (as examples mentioned in the summary) colonization, persistence, metabolic activity, immune modulation, or other pathways that could explain why responses differ across people exposed to the same probiotic.

Is this opportunity intended for early discovery of new predictors of response?

Not primarily. This R33 opportunity is described as best matched to projects that are already advanced and positioned for well-defined mechanistic testing, often supported by preliminary data that suggest specific host features may drive response. Investigators who are still at an earlier stage of identifying candidate host-response patterns are directed toward a companion R61/R33 opportunity (PAR-AT-24-XXX, TEMP-25412) for earlier development and validation steps.

What grant mechanism is used for this opportunity?

This opportunity uses the NIH R33 mechanism, which generally signals a more advanced stage of research with well-defined mechanistic testing plans, consistent with the program's emphasis on causality and translation of mechanistic insight.

Does the NOFO require preliminary data?

The summary indicates the NOFO is particularly well matched to projects where investigators already have supportive preliminary data pointing to host features that may be driving probiotic response, and where additional studies are needed to test causality, clarify mechanisms, or establish predictive value.

Are clinical trials allowed under this opportunity?

Yes. The NOFO is labeled "Clinical Trial Optional," meaning clinical trials are allowed but not required. Applicants may propose human interventional studies when appropriate, or focus on preclinical/translational mechanistic work, as long as the research directly advances a precision understanding of probiotic responsiveness.

Are projects required to be conducted in humans?

No. The NOFO calls for rigorously designed mechanistic research that can be conducted either in humans or in relevant and innovative animal models, as long as the work addresses the mechanistic and precision-focused goals described.

What kinds of methods or study designs does the NOFO emphasize?

The summary emphasizes rigorous mechanistic designs that can test how and why host factors influence probiotic function or host response. Examples mentioned include experimentally manipulating diet, immune pathways, or microbial community structure; testing defined strains or consortia under controlled conditions; using translational model systems that capture human-like variation; and applying robust analytical frameworks aimed at separating association from causal influence.

What is the overall expected output or impact of funded projects?

The expected impact is to stratify patients or consumers into meaningful biological subgroups, explain mechanistically why those subgroups respond differently, and develop practical strategies to overcome barriers that make probiotic effects inconsistent across diverse human populations.

Who is eligible to apply?

Eligibility is broad for domestic applicants and includes many types of U.S. organizations and government entities. Examples listed include state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) and small businesses; and other eligible applicants.

Are minority-serving institutions and community-based organizations included in eligible applicant types?

Yes. The NOFO highlights inclusion of organizations such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, faith-based and community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.

Are foreign organizations eligible to apply?

No. Foreign organizations are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply.

Can a project include any international or foreign components?

Yes, potentially. While foreign organizations cannot be the applicant, the summary notes that foreign components (as NIH defines them in the NIH Grants Policy Statement) may be included when justified. This allows certain international elements to contribute to the science without a foreign organization serving as the applicant.

What is the Assistance Listing (CFDA) information for this opportunity?

The summary lists Assistance Listing numbers that include 93.121, 93.213, 93.313, 93.393, and 93.866.

What is the application closing date shown in the provided information?

The posted original closing date in the summary is 2027-06-02.

Does the summary specify a budget cap or expected number of awards?

No. The provided summary states that an award ceiling and expected number of awards are not specified in the summary fields. Applicants are advised (per the summary) to confirm budget and award expectations by reviewing the full NOFO text and any NIH institute-specific guidance tied to the program.

What makes a strong fit for this R33 NOFO, based on the summary?

A strong fit is a project that is ready for well-defined mechanistic testing, ideally supported by preliminary evidence that specific host features influence probiotic response, and that proposes rigorous studies to test causality, clarify mechanisms, or establish predictive value for identifying responder subgroups and improving outcomes.